The novel natural antibiotics pyloricidin A, B and C possess potent and highly selective antibacterial activity against Helicobacter pylori. In order to investigate the structure activity relationships for the terminal peptidic moiety, a series of pyloricidin B and pyloricidin C derivatives, bearing various amino acids in the moiety, were prepared and evaluated for their were found to maintain the activity. Among the derivatives prepared in this work, the allylglycine derivative 2s showed the most potent anti-H. pylori activity, with an MIC value of of the lead compound pyloricidin C.
anti-H. pylori activity9). Therefore, we selected them as lead compounds for a therapeutically useful anti-H. pylori agent.
We have already investigated the structure activity relationships for the (2S,3R,4R,5S)-5-amino-2,3,4,brevealed that this structural unit is the minimum component of the pyloricidin antibiotics required to express anti-H. pylori activity10). Based on this finding, we speculated that the remaining peptidic moiety controls the potency of the activity and more potent derivatives might be obtained through its modification. In order to investigate the detailed structure activity relationships for the moiety, a series of pyloricidin B and pyloricidin C derivatives, in which the terminal L-valine and L-leucine were substituted with various amino acids, were prepared and evaluated for their anti-H. pylori activity. In this paper, we describe the synthesis and structure activity relationships of pyloricidin derivatives modified at the terminal peptidic moiety.
Chemistry
The pyloricidin B derivatives 1 and the pyloricidin C derivatives 2, bearing a variety of amino acids, were prepared by two general methods, as shown in Scheme 1. One method used direct condensation of the Nhydroxysuccinimide (HOSu) or N-hydroxy-5-norbornene-2,3-dicarboximide (HONB)11) esters derived from protected amino acids (P-As) with pyloricidin C or (2S,3R,4R,5S)-5-(Method A). The other method featured the condensation of P-As with the benzhydryl esters 6 or 7 derived from pyloricidin C or 4 (Method B). Although both condensation reactions were carried out without protection of the hydroxyl groups, the formation of the O-acylated byproducts was not observed. Deprotection of 5 or 8 and subsequent purification by column chromatography on MCI gel with acetonitrile-water as the eluent was followed by recrystallization to give the desired compound 1 or 2. A series of derivatives (3a-e) bearing peptide mimetics were prepared as shown in Scheme 2. The (S)-hydroxy isovaleric acid derivative 3a was prepared by the condensation of pyloricidin C with (S)-benzyloxy isovaleric acid 13, which was derived from L-valine according to the method of LI et al.12), and followed by deprotection of the benzyl group. N-Methyl-L-valine derivative 15 was coupled with pyloricidin C, followed by removal of the carbobenzoxy (Z) group to give 3b. The azadipeptide13) 18 was prepared by the successive treatment of the L-leucine 
Results and Discussion
In the previous evaluation of the anti-H. pylori activity of natural pyloricidins, pyloricidin B was found to have strong activity9). Therefore, we initially focused on pyloricidin B and examined structure activity relationships for its terminal peptidic moiety. Table 1 shows the minimum inhibitory concentrations (MICs) of the pyloricidin B derivatives, bearing various amino acids or peptidemimetics in the terminal position, against four strains of H. pylori (NCTC11637, CPY433, TN2 and TN58). As reference, the activity of pyloricidin B is also listed. Introduction of Ddecrease of the activity. On the other hand, replacement of (1e-q) was found to maintain the activity. Among the derivatives tested, the alanine derivative 1f, leucine derivative 1g, isoleucine derivative 1h, methionine derivative 1k, asparagine derivative 1m and glutamine derivative 1n showed comparable activity against the four strains to that of pyloricidin B. Whereas, the derivatives with basic or acidic amino acids (Orn (1o), Lys (1p) and Glu (1q)) showed weak activity compared with pyloricidin B. In addition, the glycine derivative 1e, phenylalanine derivative 1i, proline derivative 1j and serine derivative 1l also showed decreased activity. These findings suggested that the activity was closely associated with the terminal or methylation on amide nitrogen (3e) also lowered the activity, which might be attributed to the conformational changes resulting from modification on the dipeptide framework. From these results, it is assumed that the structure of the terminal peptidic moiety, including the be important to express anti-H. pylori activity.
Finally, we examined the anti-H. pylori activity of the pyloricidin C derivatives in which the terminal L-leucine was replaced with various amino acids ( Table 2) but conversion of the triple bond into a nitrile group (2w) drastically decreased activity. From these observations, it was concluded that the activity is closely associated with chain R2.
Conclusion
In order to investigate the structure activity relationships for the terminal peptidic moiety, a series of pyloricidin B and C derivatives, in which the terminal L-valine and Lleucine were substituted with various amino acids, were prepared and evaluated for their anti-H. pylori activity. As we speculated, the activity was closely associated with the in place of L-valine or L-leucine were found to maintain the activity. Among them, the allylglycine derivative 2s showed the most potent anti-H. pylori activity, with an MIC value Table 3 . Physicochemical data of pyloricidin derivatives 1a-y. From these result, we concluded that the terminal peptidic moiety of pyloricidins must play a critical role in controlling the potency of the anti-H. pylori activity.
Experimental
Melting points were determined using a Yanagimoto melting point apparatus and are uncorrected. IR spectra were prepared by the following general methods (Method A and Method B). The N-protected amino acids used for the preparation of 1 and 2, except for 27-29 (Table 4) , were commercially available. Compounds 27-29 were prepared according to the reported methods15,16). HCl and extracted with EtOAc. The extract was washed with brine, dried over Na2SO4, filtered and then concentrated. Finally, the protective groups were removed by the conventional methods. When the Boc or tert-butyl protective group was used, the residue was treated with 4N HCl/EtOAc or TFA at room temperature for 2 hours.
When the benzyloxycarbonyl or benzyl protective group was used, the residue was hydrogenated over 10%
palladium on charcoal at room temperature for a few hours. before being filtered. The filtrate was added to a stirred solution of 6 (657mg, 1.0mmol) or 7 (545mg, 1.0mmol)
After being stirred at room temperature for 2-72 hours, the reaction mixture was concentrated. The residue was diluted with EtOAc and water. The organic layer was separated and then washed with 5% aqueous citric acid, saturated aqueous NaHCO3 and brine before being dried over Na2SO4, filtered and concentrated. The residue was then subjected to deprotection and purification in a similar manner to that described for method A, to afford the desired compounds. The physicochemical data of 1a-y and 2a-w are listed in Table 3 and Table 4 .
N-[(2S,3R,4R,5S)-5-[N-[(2S)-2-Hydroxy-3-methylbutyryl]-alanine (3a) and N-[(2S,3R,4R,5S)-5-[N-(N-Methyl-L-valyl)-alanine (3b)
These compound were prepared from pyloricidin C and (2S)-2-benzyloxy-3-methylbutyric acid 13 or Methyl (2S)-2-Hydroxy-3-methylbutyrate (11)
To a stirred solution of 10 (5.00g, 42mmol) in MeOH (50ml) was added concentrated H2SO4 (1ml) and the mixture was refluxed for 4 hours. After being cooled to room temperature, the mixture was diluted with H2O and extracted with EtOAc. The extract was washed with saturated aqueous NaHCO3 and brine, dried over Na2SO4 and concentrated to give 11 (4.55g, 81%) as a colorless (2S)-2-Benzyloxy-3-methylbutyric Acid (13) To a solution of 12 (333mg, 1.50mmol) in MeOH (6ml) was added 1N NaOH (3ml) and the mixture was stirred at room temperature for 18 hours. The reaction mixture was acidified with 1N HCl (6ml) and extracted with EtOAc.
The extract was washed with brine, dried over Na2SO4 and concentrated to give 13 (274mg, 88%) as a colorless syrup: 
To a stirred solution of N-benzyloxycarbonyl-L-valine (2.51g, 10mmol) and iodomethane (0.69ml, 11mmol) in THE (30ml) was added NaH (60% oil suspension, MICs were defined as the lowest concentrations of the compounds preventing visible bacterial growth after four days of incubation.
